X

Drug Profile

Research programme: cancer therapeutics - Coronado Biosciences

Alternative Names: 8r; Apogossypol; CNDO 103

Latest Information Update: 09 Aug 2012

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator The Burnham Institute
Developer Coronado Biosciences
Class
Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

31 May 2011 Discontinued - Preclinical for Cancer in USA (PO)
01 Mar 2010 Preclinical development is ongoing USA
28 Jan 2008 Pharmacodynamics data from a preclinical study released by Coronado Biosciences

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com